Edwards Lifesciences (EW) Gets a Hold Rating from Credit Suisse

Credit Suisse analyst Lorenzo Biasio maintained a Hold rating on Edwards Lifesciences (EWResearch Report) yesterday and set a price target of $90.00. The company’s shares closed last Wednesday at $93.41, close to its 52-week low of $88.96.

According to, Biasio is a 4-star analyst with an average return of 7.2% and a 62.3% success rate. Biasio covers the Healthcare sector, focusing on stocks such as Coherus Biosciences, Intuitive Surgical, and Boston Scientific.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Edwards Lifesciences with a $131.33 average price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $131.73 and a one-year low of $88.96. Currently, Edwards Lifesciences has an average volume of 2.77M.

Based on the recent corporate insider activity of 146 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year. Last month, Martha Marsh, a Director at EW sold 28,722 shares for a total of $3,104,561.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.

Read More on EW:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More